Jump to content

CHMP adoptó una opinión positiva para ELZONRIS para el tratamiento de BPDCN

In The News

By In The News
in The Headlines

 Share

Recommended Posts

In The News

In The News

Posted
Posted

- CHMP adoptó una opinión positiva para ELZONRIS (tagraxofusp), para el tratamiento de la neoplasia de células dendríticas plasmacitoides blásticas (BPDCN) - El CHMP recomendó la aprobación de ELZONRIS para el tratamiento de primera línea de pacientes adultos con BPDCN - Si es aprobado...

View the full article

Link to comment
Share on other sites
Guest
Reply to this topic...

×   Pasted as rich text.   Paste as plain text instead

  Only 75 emoji are allowed.

×   Your link has been automatically embedded.   Display as a link instead

×   Your previous content has been restored.   Clear editor

×   You cannot paste images directly. Upload or insert images from URL.

×
 Share
Go to topic listing


×
×
  • Create New...